Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Oral 5-alpha reductase inhibitors do not increase breast cancer or benign breast disorder risk in women.

In this study, content analysis of German YouTube videos revealed that women frequently experience both positive and negative symptoms related to oral contraceptive use and discontinuation, with bodily sensations often influencing their decisions to start or stop the pill.

This study found that oral administration of naturally safe active polypeptides from marine shellfish promoted scarless dermal wound healing in mice, potentially via effects on inflammation, fibroblast activity, and the "skin-gut" axis.

This study evaluated oral dutasteride for male androgenetic alopecia in a real-world setting, reporting that it effectively improved hair conditions in 90% of patients using monotherapy, with a good safety profile, particularly at low doses.

In this case study, a 14-year-old female with premature hair graying showed improved hair color after treatment with a topical Melitane 5% formulation and oral hair supplements.

This article reports a case of pseudofolliculitis barbae potentially induced by the use of oral minoxidil.

In this study, higher levels of the sulfur-containing gas CH3SCH3, associated with oral malodor, were linked to MPB in elderly Japanese males, particularly when gastrointestinal and metabolic disorders were present.

This case report highlights a successful treatment with granulocyte colony-stimulating factor for cyclic neutropenia in a 16-year-old girl experiencing recurring oral aphthae and fever.

This review highlights the significant impact of cutaneous and oral mucosal adverse events on patients undergoing breast cancer treatment, emphasizing the need for early detection and comprehensive management to maintain treatment adherence and enhance patient care.

This source provides an overview of expert practices for using topical and low-dose oral minoxidil in treating hair loss, highlighting how dermatologists apply existing literature to ensure safe and effective treatment.

In this triple-blind randomized clinical trial, researchers found that oral minoxidil 0.25 mg tablets were as effective as 2% topical minoxidil for increasing hair diameter and density in women with female pattern hair loss, with similarly minor side effects.

This article reflects on the history and significance of the FDA's approval of topical minoxidil for treating androgenetic alopecia in men and women, dating back to 1988 and 1991 respectively.

This study found that oral dutasteride increased hair count more than intralesional administration in androgenetic alopecia, but more research is needed for a reliable comparison.

This study found that oral JAK3 and TYK2/JAK1 inhibitors improved clinical outcomes in alopecia areata patients by reducing immune responses and enhancing hair keratin expression, with stronger effects in those with shorter disease duration.

This study found that oral pulse steroids significantly reduced serum and tissue levels of TNF-α in patients with alopecia areata, correlating with clinical improvement.

This case report describes a 25-year-old male with multiple keratoacanthomas that responded to intralesional methotrexate and oral acitretin treatment.

This review discusses the developmental plasticity between teeth and taste buds in cichlid fishes and reports no new experimental findings, highlighting potential implications for craniofacial organ patterning and regeneration.

This study reports no new clinical results on oral zinc therapy for acrodermatitis enteropathica but provides demographic data and symptom prevalence among thirty affected children.

A woman experienced temporary hair loss after taking albendazole, which resolved on its own within 3 months.

This study found that parenteral administration of cyproterone acetate was more effective than high-dose oral treatment in reducing facial hair diameter and improving dermatological parameters in patients with severe hirsutism, despite similar androgen suppression.

Abrocitinib may help treat alopecia areata effectively with mild side effects.

This review suggests that PRF may be a promising alternative treatment for oral mucosal lesions, but further research is needed to confirm its long-term effectiveness and standardize preparation protocols.

In this case report, a 64-year-old patient with chemotherapy-induced alopecia was treated with oral minoxidil and experienced good results, suggesting a potential new therapy for this challenging condition.

Low-dose oral minoxidil increases hair density and thickness in people with hair loss.

In this study, oral mini-pulse methylprednisolone therapy for alopecia areata was reported to be effective and safe over 6 months, with 82.2% of patients recovering well and no adverse events observed.

This study found that among patients with stage III and IV androgenic alopecia, 83% of those using topical 5% minoxidil with topical 0.1% finasteride showed improved hair density, suggesting it may reduce the need for long-term oral finasteride.

This study reports significant hair regrowth in 11 patients with severe alopecia areata following longstanding treatment with oral tofacitinib and also highlights successful treatment using topical tofacitinib cream in one case.

This study reported dramatic improvements in five collodion baby patients with lamellar ichthyosis treated with oral retinoic acid, noting hair loss as the sole adverse effect, emphasizing the treatment's promising efficacy for physicians.

This case report observed that after 6 months of treatment with topical cetirizine and oral vitamin D, hair density and quality improved in three girls with congenital hypotrichosis due to ectodermal dysplasia.

This article details various skin and oral lesions through illustrative figures but does not present new research results.